Lv5
1270 积分 2022-01-20 加入
Evaluating extraprostatic extension of prostate cancer: pragmatic integration of MRI and PSMA-PET/CT
28天前
已完结
The long tail of oncogenic drivers in prostate cancer
1个月前
已完结
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
1个月前
已完结
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
1个月前
已完结
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
1个月前
已完结
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
1个月前
已完结
PARP inhibitors: Synthetic lethality in the clinic
1个月前
已完结
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
1个月前
已完结
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
1个月前
已完结
皖公网安备34019202002308
